UBS Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

UBS Group’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-250	Closed	–	–	8863
2019 Q4	$0	Hold	250	–	–	﹤0.01%	8671
2019 Q3	$1K	Buy	250 +40	+19%	+$144	﹤0.01%	7923
2019 Q2	$1K	Hold	210	–	–	﹤0.01%	7797
2019 Q1	$1K	Sell	210 -2,568	-92%	-$13.9K	﹤0.01%	7630
2018 Q4	$11K	Buy	2,778 +109	+4%	+$1.39K	﹤0.01%	7213
2018 Q3	$53K	Buy	2,669 +1,830	+218%	+$46.3K	﹤0.01%	6123
2018 Q2	$27K	Buy	839 +488	+139%	+$17.6K	﹤0.01%	6491
2018 Q1	$13K	Sell	351 -406	-54%	-$26.7K	﹤0.01%	6741
2017 Q4	$59K	Buy	+757	New	+$56K	﹤0.01%	5715

UBS Group's MLNT Position: Q1 2020 in Review

UBS Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 250 shares.

UBS Group first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $59K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

UBS Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
UBS Group sold 250 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
UBS Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
UBS Group's Melinta Therapeutics, Inc. Common Stock position peaked at $59K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.